STTR Phase II: Development of a Smart Remote Health Management System for Patients with Kidney Disease

STTR二期：为肾病患者开发智能远程健康管理系统

• 批准号: 2243718
• 负责人: Sathya Elumalai
• 金额: $ 100万
• 依托单位: AIDAR HEALTH, INC
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-10-01 至 2025-09-30
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2243718&HistoricalAwards=false
• 关键词: STTR; Phase; II; Development; Smart

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project is to develop a novel technology for the early detection of complications and effective management of kidney disease at home. More than 37 million patients in the US have chronic kidney disease, which is associated with increased mortality and morbidity, including a greater risk of cardiovascular disease, hospitalization, premature death, and progression to end-stage kidney disease. According to the Centers for Disease Control and Prevention, in 2018, treating Medicare beneficiaries with chronic kidney disease cost over $81 billion, and approximately 20% of the Medicare budget was spent on kidney disease. This project leverages a medical device and digital tools with advanced analytics capabilities to provide actionable data and key health insights for timely interventions for at-risk patients. There is a rapid shift towards value-based healthcare from the traditional fee-for-service model accelerated by the significant cost burden and poor outcomes, especially in kidney care management. This solution is designed to facilitate this transition seamlessly, lowering unnecessary emergency room visits and/or hospitalizations, and minimizing exacerbations and associated healthcare costs in a disease condition that contributes over $100 billion in healthcare expenses.This STTR Phase II project develops a comprehensive disease management solution for chronic kidney disease by offering a personalized clinical-decision support system for providers as well as a companion diagnostic solution for patients to improve therapeutic benefits. There is a dearth of reliable and accurate predictive tools that can non-invasively measure critical biophysical and biochemical markers to inform clinical care and empower self-identification of undesirable effects. The objective of this research is to develop and validate disruptive technologies for the non-invasive assessment of biomarkers critical to chronic kidney disease diagnosis and management such as hemoglobin levels, electrocardiography (ECG)-based arrhythmia, estimated potassium levels, and lung functions, augmenting the existing capability that measure 10+ vital signs. The innovation also includes a novel concept for any medical device, to record and broadcast personalized messages in a trusted voice (physician/family member), to improve treatment adherence and outcomes. The project further incorporates a proprietary cloud-based analytics system that leverages both subjective and objective data to generate a unique ‘digital fingerprint’ for effective management and triage. Consistent use of the proposed solution will improve symptoms management, care delivery, and diagnosis, and ultimately lead to dramatic reductions in hospitalizations, total medical expenditure related to morbidity and lost productivity, and patient anxiety.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业技术转让（STTR）第二阶段项目的更广泛的影响/商业潜力是开发一种新技术，用于早期发现并发症和在家中有效管理肾脏疾病。在美国，超过3700万患者患有慢性肾脏疾病，这与死亡率和发病率增加有关，包括心血管疾病、住院治疗、过早死亡和进展为终末期肾脏疾病的风险增加。根据疾病控制和预防中心的数据，2018年，治疗慢性肾脏疾病的医疗保险受益人花费超过810亿美元，大约20%的医疗保险预算用于肾脏疾病。该项目利用具有高级分析功能的医疗设备和数字化工具，为高危患者提供可操作的数据和关键健康见解，以便及时采取干预措施。从传统的按服务收费模式向基于价值的医疗保健的快速转变，由于显著的成本负担和不良结果而加速，特别是在肾脏护理管理方面。该解决方案旨在无缝地促进这种过渡，减少不必要的急诊室就诊和/或住院，并最大限度地减少疾病的恶化和相关的医疗保健费用，这些疾病的医疗保健费用超过1000亿美元。这个STTR II期项目通过提供个性化的临床-提供者的决策支持系统以及患者的伴随诊断解决方案，以提高治疗效益。缺乏可靠和准确的预测工具，可以非侵入性地测量关键的生物物理和生化标志物，以告知临床护理并使自我识别不良反应。这项研究的目的是开发和验证用于非侵入性评估对慢性肾脏疾病诊断和管理至关重要的生物标志物的颠覆性技术，如血红蛋白水平，基于心电图（ECG）的心律失常，估计钾水平和肺功能，增强测量10+生命体征的现有能力。该创新还包括一个适用于任何医疗设备的新概念，以可信的声音（医生/家庭成员）记录和广播个性化消息，以改善治疗依从性和结果。该项目还集成了一个专有的基于云的分析系统，该系统利用主观和客观数据生成独特的“数字指纹”，以进行有效的管理和分流。持续使用所提出的解决方案将改善症状管理、护理提供和诊断，并最终导致住院、与发病率和生产力损失相关的总医疗支出以及患者焦虑的大幅减少。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。